Trisalus Life Sciences Inc (TLSI) Stock Price, Quote & News

Company Profile

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde...

Industry: Medical Devices

Sector: Healthcare

Phone: 888 321 5212

Website: trisaluslifesci.com

Address:

6272 West 91st Avenue, Westminster, United States

AccuRoger Mar. 18 at 12:41 PM

$TLSI This is a human trial in progress. The abstract is embargoed at the moment. FYI

0 · Reply

DARKP00L Mar. 18 at 12:09 PM

$TLSI 08:07 on Mar. 18 2026 TriSalus Life Sciences Publishes Preclinical Research Evaluating Pressure-Enabled Drug Delivery Of Nelitoliod In Liver Tumor Models In 'Frontiers In Oncology' #tradeideas

0 · Reply

AccuRoger Mar. 15 at 7:07 PM

$TLSI This is a recent article regarding Nelitolimod side effects. It does not change the share price, but it is helpful detail about the low risk related to this therapy across multiple uses. https://pubmed.ncbi.nlm.nih.gov/41819640/

0 · Reply

DonCorleone77 Mar. 6 at 2:09 AM

$TLSI TriSalus Life Sciences sees FY26 revenue $60M-$62M, consensus $60.34M The Company anticipates 2026 revenues in the range of $60 million to $62 million.

0 · Reply

DonCorleone77 Mar. 6 at 2:09 AM

$TLSI TriSalus Life Sciences reports Q4 EPS (21c), consensus (14c) Reports Q4 revenue $13.205M vs $8.261M last year. "During our fourth quarter and throughout 2025, we continued to deliver strong commercial performance, supported by the growing clinical adoption of our TriNav product suite and proprietary PEDD platform across a broad range of solid tumor indications," said Mary Szela, President and CEO of TriSalus. "We are pleased to have exceeded our 2025 revenue guidance of 50%, delivering 53%, reflecting strong commercial execution and sustained progress on our strategic initiatives, including expansion of the TriNav platform across multiple indications beyond the liver."

0 · Reply

StocktwitsEarnings Mar. 5 at 9:11 PM

$TLSI Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.21 up 47.50% YoY • Reported revenue of $13.21M up 59.85% YoY • TriSalus anticipates 2026 revenues in the range of $60M to $62M, reaffirming its prior guidance. TriSalus expects to deepen engagement, expand sales, and invest in studies to demonstrate PEDD value.

0 · Reply

StocktwitsEarnings Mar. 5 at 9:11 PM

$TLSI Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.21 up 47.50% YoY • Reported revenue of $13.21M up 59.85% YoY • TriSalus Life Sciences reaffirms its 2026 revenue guidance, anticipating revenues to be in the range of $60M to $62M, reflecting confidence in commercial opportunities and long-term vision.

0 · Reply

topstockalerts Feb. 24 at 2:25 PM

$TLSI heating up…

0 · Reply

PLATINUM_TRADES Feb. 23 at 1:06 PM

$TLSI Let's have another good day! $5.89 Major resistance to break for more 🚨 🚨

0 · Reply

StockScanners Feb. 21 at 6:16 AM

$TLSI keep watch if this holds above 5.50

0 · Reply

Market Cap	240.93M
Revenue (ttm)	45.15M
Net Income (ttm)	-39.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-86.89%
Debt to Equity Ratio	-0.98

Volume	396,200
Avg Vol	184,250
Day's Range	N/A - N/A
Shares Out	61.31M
Stochastic %K	24%
Beta	0.42
Analysts	Strong Sell
Price Target	$10.10